{
    "id": 338,
    "fullName": "TP53 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TP53 mutant indicates an unspecified mutation within the TP53 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "mutant",
    "createDate": "03/13/2014",
    "updateDate": "08/29/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4017,
                "therapyName": "Etoposide + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5272,
                    "pubMedId": 25964101,
                    "title": "Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18927,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "TP53 mutations are associated with a poor prognosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13542,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2325,
                "therapyName": "Idelalisib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3414,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1211,
                "therapyName": "Pazopanib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3774,
                    "pubMedId": 25669829,
                    "title": "Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25669829"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12572,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy resulted in a response rate of 100% (14/14, 9 complete response, 5 partial response) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, and a response rate of 100% (16/16, 9 complete response, 7 partial response) in untreated patients with high-risk features including del 17p, TP53 mutations, and del 11q (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 429; NCT02756897).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10439,
                    "pubMedId": null,
                    "title": "Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper106923.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6065,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5272,
                    "pubMedId": 25964101,
                    "title": "Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8263,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3402,
                "therapyName": "NSC59984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4303,
                    "pubMedId": 26294215,
                    "title": "Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 138,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 851,
                "therapyName": "PD0166285",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 209,
                    "pubMedId": 11719452,
                    "title": "Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11719452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1149,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4186,
                "therapyName": "Adavosertib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 898,
                    "pubMedId": 21992793,
                    "title": "Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21992793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19237,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Brukinsa (zanubrutinib) treatment resulted in an overall response rate of 100% (16/16) in patients with CLL/SLL harboring del (17p) or TP53 mutations (PMID: 31340982; NCT02343120).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2544,
                "therapyName": "Zanubrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16806,
                    "pubMedId": 31340982,
                    "title": "Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31340982"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3413,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) improved progression-free survival and overall survival in advanced solid tumor patients harboring TP53 hotspot mutations, and resulted in an increased stable disease rate of 45% (5/11), compared to a stable disease rate of 16% (4/25) in patients without detected TP53 mutations (PMID: 25669829).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1211,
                "therapyName": "Pazopanib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3774,
                    "pubMedId": 25669829,
                    "title": "Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25669829"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5574,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11113,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53-mutated breast cancer cell lines demonstrated increased sensitivity to PK11007 compared to TP53-wild type cells in culture, regardless of Esr1 and Erbb2 (Her2) status (J Clin Oncol 35, 2017 (suppl; abstr e14099)).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5862,
                "therapyName": "PK11007",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9085,
                    "pubMedId": null,
                    "title": "Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?",
                    "url": "http://abstracts.asco.org/199/AbstView_199_189403.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18933,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Copiktra (duvelisib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1024,
                "therapyName": "Duvelisib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18053,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Dacogen (decitabine) is included in guidelines for adult patients with acute myeloid leukemia harboring a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19862,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment inhibited tumor growth but did not induce regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM and TP53 mutation (PMID: 31699977).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10956,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with triple-receptor negative breast cancer harboring a TP53 mutation (PMID: 27815358).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5734,
                "therapyName": "GDC-0425 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8959,
                    "pubMedId": 27815358,
                    "title": "Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27815358"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13540,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3937,
                "therapyName": "Rituximab + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20760,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with non-small cell lung cancer harboring TP53 mutations at treatment discontinuation of Tagrisso (osimertinib) had shorter time to treatment discontinuation (6.5 vs 11.5 months, p=0.0029) compared to patients with wild-type TP53 (PMID: 31839416).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18931,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Calquence (acalabrutinib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1605,
                "therapyName": "Acalabrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1505,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1755,
                "therapyName": "AZD7762 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1211,
                    "pubMedId": 23839309,
                    "title": "Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23839309"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15280,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 30% (3/10) of patients with acute myeloid leukemia harboring TP53 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3182,
                "therapyName": "Cytarabine + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12984,
                    "pubMedId": null,
                    "title": "Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy",
                    "url": "https://ash.confex.com/ash/2018/webprogram/Paper118729.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9183,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4928,
                "therapyName": "Carboplatin + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7000,
                    "pubMedId": 26494859,
                    "title": "Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26494859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11765,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in an overall response rate of 43% (9/21), a median progression-free survival of 5.3 months and a median overall survival of 12.6 months in ovarian cancer patients harboring TP53 mutations (PMID: 27998224).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14020,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival (HR=0.52) and prolonged progression-free survival (HR=0.45) in head and neck squamous cell carcinoma patients harboring TP53 mutations compared to TP53 wild-type patients (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12763,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant breast carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 6626,
                "therapyName": "Camptothecin + CHIR-124",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10687,
                    "pubMedId": 17255282,
                    "title": "CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17255282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18930,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Venclexta (venetoclax) and Gazyva (obinutuzumab) is indicated in the guidelines as first line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3636,
                "therapyName": "Obinutuzumab + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10906,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-mutant triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 26826118).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5678,
                "therapyName": "Doxorubicin + Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8919,
                    "pubMedId": 26826118,
                    "title": "Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13538,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Imbruvica (ibrutinib) is indicated in the guidelines as first line therapy and relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5145,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Copiktra (duvelisib) treatment inhibited Akt phosphorylation, resulted in complete response in 2% (1/49), partial response in 53% (26/49), and stable disease in 43% (21/49) of chronic lymphocytic leukemia patients, of which 49% (23/47) carried TP53 mutations (Blood 124 (21): 3334).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1024,
                "therapyName": "Duvelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4888,
                    "pubMedId": null,
                    "title": "Duvelisib (IPI-145), a PI3K-?,? Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia",
                    "url": "http://www.bloodjournal.org/content/124/21/3334.abstract?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3424,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1211,
                "therapyName": "Pazopanib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3774,
                    "pubMedId": 25669829,
                    "title": "Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25669829"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5068,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4871,
                    "pubMedId": 26459177,
                    "title": "Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26459177"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20084,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Calquence (acalabrutinib) combined with Gazyva (obinutuzumab) is indicated in the guidelines as first-line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3477,
                "therapyName": "Acalabrutinib + Obinutuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1133,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 878,
                    "pubMedId": 24231268,
                    "title": "BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24231268"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9288,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I trial, Adavosertib (MK-1775) combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7062,
                    "pubMedId": 27601554,
                    "title": "Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27601554"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19860,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment induced tumor regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring TP53 mutation and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13651,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "TP53 mutations except P47S and P72R are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50908,
                "name": "myelodysplastic syndrome",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2994,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1582,
                "therapyName": "MI-63",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5770,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 209,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 79,
                    "pubMedId": 23670029,
                    "title": "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23670029"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18093,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "TP53 mutations are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4578,
                "therapyName": "unspecified EGFR antibody + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 8533,
                "name": "hypopharynx cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4932,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 vs 136 days, p=0.036) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4803,
                    "pubMedId": 26646755,
                    "title": "TP53 mutational status is predictive of pazopanib response in advanced sarcomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26646755"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5283,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13723,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 2224,
                "name": "essential thrombocythemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13716,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "TP53 mutations are associated with inferior leukemia-free survival in patients with essential thrombocythemia (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 2224,
                "name": "essential thrombocythemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2993,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13988,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0575 and Gemzar (gemcitabine) combination treatment inhibited tumor growth, prolonged progression-free survival in patient-derived xenogrft (PDX) models of undifferentiated pleomorphic sarcoma (fibrous histiocytoma) (PMID: 29409053).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4415,
                "name": "fibrous histiocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13989,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0575 and Gemzar (gemcitabine) combination treatment resulted in a prolonged tumor response in 2 soft tissue sarcoma patients harboring TP53 mutations, and no response in a patient with TP53 wild-type tumor (PMID: 29409053; NCT01564251).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10736,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 2999,
                "therapyName": "thioureidobutyronitrile",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8790,
                    "pubMedId": null,
                    "title": "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7043,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Adavosertib (MK-1775) decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6050,
                    "pubMedId": 27196784,
                    "title": "Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12762,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant colon carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 6626,
                "therapyName": "Camptothecin + CHIR-124",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10687,
                    "pubMedId": 17255282,
                    "title": "CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17255282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18097,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15995,
                    "pubMedId": 31097096,
                    "title": "Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31097096"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7782,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4579,
                "therapyName": "unspecified EGFR antibody + unspecified ERBB3 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 8533,
                "name": "hypopharynx cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 722,
                "therapyName": "DS-7423",
                "synonyms": null
            },
            "indication": {
                "id": 5304,
                "name": "ovarian clear cell adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4912,
                    "pubMedId": 24504419,
                    "title": "Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24504419"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16854,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia cells harboring TP53 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 7038,
                "therapyName": "CG-806",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14956,
                    "pubMedId": null,
                    "title": "CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7777,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr did not inhibit proliferation of Tp53 mutated hypopharyngeal carcinoma cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4575,
                "therapyName": "unspecified EGFR antibody",
                "synonyms": null
            },
            "indication": {
                "id": 8533,
                "name": "hypopharynx cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13544,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Venclexta (venetoclax) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10017,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 50921,
                "name": "pharynx squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7784,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 4580,
                "therapyName": "unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 8533,
                "name": "hypopharynx cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6493,
                    "pubMedId": 27196767,
                    "title": "Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18095,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15995,
                    "pubMedId": 31097096,
                    "title": "Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31097096"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11294,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9220,
                    "pubMedId": 28039262,
                    "title": "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28039262"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18096,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15995,
                    "pubMedId": 31097096,
                    "title": "Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31097096"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4556,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 3537,
                "therapyName": "CEP-8983 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4605,
                    "pubMedId": 23428903,
                    "title": "Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23428903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a tongue squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 50865,
                "name": "tongue squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19864,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of ovarian cancer harboring a TP53 mutation and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16697,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, VEGF/VEGFR inhibitor treatment resulted in improved rates of response (stable disease over 6 months/partial/complete response, 31% vs 7%), time-to-treatment failure, and overall survival (both p<0.01) compared to control in patients with TP53 mutant advanced solid tumors (n=106), but not in patients with TP53 wild-type tumors (n=82) (PMID: 27466356).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 8151,
                "therapyName": "Unspecified VEGFR inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6495,
                    "pubMedId": 27466356,
                    "title": "TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27466356"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13782,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in TP53 result in Li-Fraumeni syndrome, which is associated with increased risk of developing osteosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) prevented cell growth and inhibited MTORC1 and MTORC2 signaling in rapamycin-resistant breast cancer cells harboring mutations in BRAF, CDKN2A, KRAS,NF2 and TP53 (PMID: 25261369).",
            "molecularProfile": {
                "id": 5003,
                "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",
            "molecularProfile": {
                "id": 5387,
                "profileName": "PTEN mut TP53 mut"
            },
            "therapy": {
                "id": 5245,
                "therapyName": "Navitoclax + ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7647,
                    "pubMedId": 26474387,
                    "title": "TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26474387"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).",
            "molecularProfile": {
                "id": 5387,
                "profileName": "PTEN mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4159,
                "name": "skin cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).",
            "molecularProfile": {
                "id": 5389,
                "profileName": "PTEN mut RB1 mut SMAD4 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4159,
                "name": "skin cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2135,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).",
            "molecularProfile": {
                "id": 5415,
                "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4357,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).",
            "molecularProfile": {
                "id": 17821,
                "profileName": "RB1 mut TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4351,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).",
            "molecularProfile": {
                "id": 17821,
                "profileName": "RB1 mut TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4358,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17821,
                "profileName": "RB1 mut TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4359,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4361,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4355,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4352,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4739,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18890,
                "profileName": "ALK wild-type TP53 mut"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5037,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 treatment, which requires an intact P53 response, had no effect on a breast cancer cell line co-harboring PPM1D amplification and a TP53 mutation (PMID: 24390428).",
            "molecularProfile": {
                "id": 20119,
                "profileName": "PPM1D amp TP53 mut"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4845,
                    "pubMedId": 24390428,
                    "title": "Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24390428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Tp73 expression via shRNA resulted in reduced sensitivity to Nutlin-3 and Paraplatin (carboplatin) combination treatment in TP53 mutated triple-receptor negative breast cancer cell lines in culture (PMID: 26494859).",
            "molecularProfile": {
                "id": 21575,
                "profileName": "TP53 mut TP73 dec exp"
            },
            "therapy": {
                "id": 4928,
                "therapyName": "Carboplatin + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7000,
                    "pubMedId": 26494859,
                    "title": "Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26494859"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5773,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down Tp73 reduced Prodigiosin induced inhibition of self-renewal in colorectal cancer cell lines harboring Tp53 mutations (PMID: 26759239).",
            "molecularProfile": {
                "id": 21575,
                "profileName": "TP53 mut TP73 dec exp"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to LY3009120 mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6620,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6618,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6998,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate (DCR) of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib), compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).",
            "molecularProfile": {
                "id": 24178,
                "profileName": "EGFR mut TP53 mut"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11253,
                    "pubMedId": 27780855,
                    "title": "Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780855"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11296,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9220,
                    "pubMedId": 28039262,
                    "title": "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28039262"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7460,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13939,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated a greater objective response rate (35.7% vs 7.4% vs 28.6%), longer PFS (3.0mo vs 1.8 vs 2.7) and OS (16mo vs 6.4 vs 16.1) compared to patients with KRAS and STK11 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 5316,
                "therapyName": "Alpelisib + Erlotinib + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13942,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated an objective response rate (ORR) of 57.1% (4/7) when treated with Opdivo (nivolumab) compared to an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8082,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LEQ506 inhibited cell growth, induced apoptosis in tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice which also harbored TP53 mutations in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26145,
                "profileName": "PTCH1 inact mut TP53 mut"
            },
            "therapy": {
                "id": 2416,
                "therapyName": "LEQ506",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8077,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited cell growth, induced apoptosis in tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice which also harbored TP53 mutations in culture, and suppressed tumor growth in xenograft models (PMID: 26130651).",
            "molecularProfile": {
                "id": 26145,
                "profileName": "PTCH1 inact mut TP53 mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8080,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erivedge (vismodegib) inhibited cell growth, induced apoptosis in tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice which also harbored TP53 mutations in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26145,
                "profileName": "PTCH1 inact mut TP53 mut"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, treatment with the combination of Alisertib (MLN8327) and Platinol (cisplatin) resulted in increased apoptosis and decreased growth of TP53-mutant esophageal adenocarcinoma cell lines with AURKA amplfication and overexpression in culture, and increased tumor growth inhibition in xenograft models compared to either agent alone (PMID: 22302096).",
            "molecularProfile": {
                "id": 27055,
                "profileName": "AURKA amp TP53 mut"
            },
            "therapy": {
                "id": 5195,
                "therapyName": "Alisertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 60,
                    "pubMedId": 22302096,
                    "title": "The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22302096"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9934,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 27213,
                "profileName": "BRAF mut TP53 mut"
            },
            "therapy": {
                "id": 5318,
                "therapyName": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13781,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The combination of TP53 mutation and SHH activating mutation is associated with aggressive disease in patients with medulloblastoma (NCCN.org).",
            "molecularProfile": {
                "id": 29416,
                "profileName": "SHH act mut TP53 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13947,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients negative for CD274 and co-harboring a KRAS mutation and TP53 mutation treated with a PD-1 inhibitor demonstrated a greater objective response rate compared to CD274-negative patients harboring either mutant KRAS only or co-harboring a KRAS mutation and STK11 mutation, 30% (3/10) vs 5.9% (1/17) vs 5.3% (1/19), respectively (PMID: 29773717).",
            "molecularProfile": {
                "id": 29888,
                "profileName": "CD274 neg KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15162,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15163,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16487,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039), and a lower median overall survival with treatment with Zykadia (ceritinib) after Xalkori (crizotinib) of 7.0 mo. vs. 50.0 mo. in patients with wild-type TP53 (p=0.001) (PMID: 30165392).",
            "molecularProfile": {
                "id": 31641,
                "profileName": "ALK rearrange TP53 mut"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14534,
                    "pubMedId": 30165392,
                    "title": "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16489,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).",
            "molecularProfile": {
                "id": 31641,
                "profileName": "ALK rearrange TP53 mut"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14534,
                    "pubMedId": 30165392,
                    "title": "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16486,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Xalkori (crizotinib) as a first line therapy or after chemotherapy vs. patients with wild-type TP53 (5.0 mo., n=22 vs. 14.0 mo., n=71; p<0.001), and a lower median overall survival (17.0 mo., n=13 vs. not reached n=50; p=0.049) (PMID: 30165392).",
            "molecularProfile": {
                "id": 31641,
                "profileName": "ALK rearrange TP53 mut"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14534,
                    "pubMedId": 30165392,
                    "title": "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16488,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).",
            "molecularProfile": {
                "id": 31641,
                "profileName": "ALK rearrange TP53 mut"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14534,
                    "pubMedId": 30165392,
                    "title": "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30165392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17686,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Xalkori (crizotinib) demonstrated a shorter median progression-free survival in patients with non-small cell lung cancer co-harboring a ROS1 rearrangement and TP53 mutation compared to patients with a ROS1 rearrangement and wild-type TP53 (7 vs. 24.1 months; p=0.022) (PMID: 30978502; NCT02183870).",
            "molecularProfile": {
                "id": 32738,
                "profileName": "TP53 mut ROS1 rearrange"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15732,
                    "pubMedId": 30978502,
                    "title": "Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30978502"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19863,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19859,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment induced tumor regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19861,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment inhibited tumor growth but did not induce regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19481,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited viability of triple-negative breast cancer cells harboring wild-type ATM in culture, and induced tumor regression in a patient-derived xenograft (PDX) model harboring wild-type ATM, TP53 and BRCA2 mutations, CCNE1 amplification, and CDKN2A deletion (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth, however, with decreased response compared to AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination treatment synergistically inhibited tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8901,
                "therapyName": "AZD7648 + Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 434,
            "profileName": "TP53 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5003,
            "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5387,
            "profileName": "PTEN mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5389,
            "profileName": "PTEN mut RB1 mut SMAD4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5415,
            "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17821,
            "profileName": "RB1 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17822,
            "profileName": "RB1 wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18890,
            "profileName": "ALK wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20119,
            "profileName": "PPM1D amp TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21575,
            "profileName": "TP53 mut TP73 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23647,
            "profileName": "SMARCA4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24178,
            "profileName": "EGFR mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25456,
            "profileName": "KRAS mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26145,
            "profileName": "PTCH1 inact mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27055,
            "profileName": "AURKA amp TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27213,
            "profileName": "BRAF mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29416,
            "profileName": "SHH act mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29888,
            "profileName": "CD274 neg KRAS mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30811,
            "profileName": "EGFR wild-type STK11 wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31641,
            "profileName": "ALK rearrange TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32738,
            "profileName": "TP53 mut ROS1 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34553,
            "profileName": "ATM wild-type BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34555,
            "profileName": "ATM wild-type BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34556,
            "profileName": "ATM wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34748,
            "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34749,
            "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}